Best Practice & Research Clinical Rheumatology
Volume 21, Issue 3 , Pages 499-511, June 2007

Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain

  • Don L. Goldenberg, MD (Chief, Rheumatology, Newton-Wellesley Hospital, and Professor of Medicine, Tufts University School of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 617 243 5440; Fax: +1 617 243 6453.

Newton-Wellesley Hospital, Division of Rheumatology, 2000 Washington Street, Suite 304, Newton, MA 02468, USA

The pharmacologic management of fibromyalgia is based on the emerging evidence that pain in this disorder is primarily related to central pain sensitization. There is strong evidence that tricyclic antidepressants are effective, and moderate evidence for the effectiveness of serotonin reuptake inhibitors and dual serotonin–norepinephrine reuptake inhibitors. Recent work suggests that the anti-seizure medications pregabalin and gabepentin are also effective. The only analgesic demonstrated to be helpful is tramadol.

Key words: pharmacologic management of fibromyalgia, central pain sensitization, tricyclic antidepressants, serotonin reuptake inhibitors, dual serotonin–norepinephrine reuptake inhibitors, anti-seizure medications, tramadol

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(07)00028-9

doi:10.1016/j.berh.2007.02.012

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 3 , Pages 499-511, June 2007